thrombin receptor antagonist Latest Research Papers

Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

American Heart Journal ◽

10.1016/j.ahj.2017.10.007 ◽

2018 ◽

Vol 196 ◽

pp. 28-35 ◽

Cited By ~ 5

Author(s):

Patrícia O. Guimarães ◽

Sergio Leonardi ◽

Zhen Huang ◽

Lars Wallentin ◽

Frans Van de Werf ◽

...

Keyword(s):

Myocardial Infarction ◽

Acute Coronary Syndrome ◽

Receptor Antagonist ◽

Clinical Features ◽

Clinical Event ◽

Thrombin Receptor ◽

Coronary Syndrome ◽

Thrombin Receptor Antagonist

Download Full-text

Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial

European Heart Journal ◽

10.1093/eurheartj/ehw525 ◽

2016 ◽

pp. ehw525 ◽

Cited By ~ 16

Author(s):

Marco Valgimigli ◽

Francesco Costa ◽

Yuliya Lokhnygina ◽

Robert M. Clare ◽

Lars Wallentin ◽

...

Keyword(s):

Myocardial Infarction ◽

Acute Coronary Syndrome ◽

Randomized Trial ◽

Receptor Antagonist ◽

Clinical Event ◽

Thrombin Receptor ◽

Trade Off ◽

Coronary Syndrome ◽

Thrombin Receptor Antagonist

Download Full-text

Effect of age on efficacy and safety of vorapaxar in patients with non–ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

American Heart Journal ◽

10.1016/j.ahj.2016.05.012 ◽

2016 ◽

Vol 178 ◽

pp. 176-184 ◽

Cited By ~ 4

Author(s):

Luciana V. Armaganijan ◽

Karen P. Alexander ◽

Zhen Huang ◽

Pierluigi Tricoci ◽

Claes Held ◽

...

Keyword(s):

Acute Coronary Syndrome ◽

Receptor Antagonist ◽

Clinical Event ◽

Thrombin Receptor ◽

Efficacy And Safety ◽

St Segment Elevation ◽

Coronary Syndrome ◽

St Segment ◽

Thrombin Receptor Antagonist ◽

Effect Of Age

Download Full-text

Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)‐TIMI 50

Journal of the American Heart Association ◽

10.1161/jaha.116.003237 ◽

2016 ◽

Vol 5 (7) ◽

Cited By ~ 10

Author(s):

Stephen K. Kidd ◽

Marc P. Bonaca ◽

Eugene Braunwald ◽

Gaetano M. De Ferrari ◽

Basil S. Lewis ◽

...

Keyword(s):

Myocardial Infarction ◽

Secondary Prevention ◽

Receptor Antagonist ◽

Classification System ◽

Thrombin Receptor ◽

System Type ◽

Ischemic Events ◽

Thrombin Receptor Antagonist

Download Full-text

TRADEOFF BETWEEN MYOCARDIAL INFARCTION VERSUS BLEEDING TYPES ON MORTALITY AFTER ACUTE CORONARY SYNDROME: LESSONS FROM THE THROMBIN RECEPTOR ANTAGONIST FOR CLINICAL EVENT REDUCTION IN ACUTE CORONARY SYNDROME (TRACER) RANDOMIZED TRIAL

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(16)30457-0 ◽

2016 ◽

Vol 67 (13) ◽

pp. 456

Author(s):

Francesco Costa ◽

Marco Valgimigli ◽

Yuliya Lokhnygina ◽

Robert Clare ◽

Lars Wallentin ◽

...

Keyword(s):

Myocardial Infarction ◽

Acute Coronary Syndrome ◽

Randomized Trial ◽

Receptor Antagonist ◽

Clinical Event ◽

Thrombin Receptor ◽

Coronary Syndrome ◽

Thrombin Receptor Antagonist

Download Full-text

In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist

European Journal of Pharmacology ◽

10.1016/j.ejphar.2015.05.046 ◽

2015 ◽

Vol 762 ◽

pp. 221-228 ◽

Cited By ~ 9

Author(s):

Brian E. Hawes ◽

Ying Zhai ◽

David Hesk ◽

Mark Wirth ◽

Huijun Wei ◽

...

Keyword(s):

Receptor Antagonist ◽

Thrombin Receptor ◽

Pharmacological Characterization ◽

Thrombin Receptor Antagonist

Download Full-text

Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist

European Journal of Pharmacology ◽

10.1016/j.ejphar.2015.03.073 ◽

2015 ◽

Vol 758 ◽

pp. 107-114 ◽

Cited By ~ 11

Author(s):

Tian-Quan Cai ◽

L. Alexandra Wickham ◽

Gary Sitko ◽

Maria Strainer Michener ◽

Richard Raubertas ◽

...

Keyword(s):

Receptor Antagonist ◽

Platelet Transfusion ◽

Thrombin Receptor ◽

Anti Platelet Therapy ◽

Thrombin Receptor Antagonist

Download Full-text

Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non–ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)

The American Journal of Cardiology ◽

10.1016/j.amjcard.2015.02.043 ◽

2015 ◽

Vol 115 (10) ◽

pp. 1325-1332 ◽

Cited By ~ 11

Author(s):

Jan H. Cornel ◽

Pierluigi Tricoci ◽

Yuliya Lokhnygina ◽

David J. Moliterno ◽

Lars Wallentin ◽

...

Keyword(s):

Receptor Antagonist ◽

Acute Coronary Syndromes ◽

Thrombin Receptor ◽

St Segment Elevation ◽

St Segment ◽

Coronary Syndromes ◽

Thrombin Receptor Antagonist

Download Full-text

Efficacy and Safety of Thrombin-Receptor Antagonist (Atopaxar and Vorapaxar) in Patients with Acute Coronary Syndrome or Coronary Artery Disease—A Meta-Analysis of Randomized Controlled Trials

Value in Health Regional Issues ◽

10.1016/j.vhri.2015.01.003 ◽

2015 ◽

Vol 6 ◽

pp. 22-32 ◽

Cited By ~ 2

Author(s):

Lan Gao ◽

Fei-Li Zhao ◽

Shu-Chuen Li

Keyword(s):

Coronary Artery Disease ◽

Acute Coronary Syndrome ◽

Meta Analysis ◽

Thrombin Receptor ◽

Controlled Trials ◽

Efficacy And Safety ◽

Coronary Syndrome ◽

Randomized Controlled ◽

Artery Disease ◽

Thrombin Receptor Antagonist

Download Full-text

Selection of a Suitable Patient Population for New Antiplatelet Therapy From the Large Clinical Trial Database of the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events–Thrombolysis in Myocardial Infarction 50 (TRA-2P–TIMI50) Trial

Circulation ◽

10.1161/circulationaha.115.015471 ◽

2015 ◽

Vol 131 (12) ◽

pp. 1041-1043 ◽

Cited By ~ 7

Author(s):

Shinichi Goto ◽

Shinya Goto

Keyword(s):

Myocardial Infarction ◽

Clinical Trial ◽

Secondary Prevention ◽

Receptor Antagonist ◽

Patient Population ◽

Thrombin Receptor ◽

Large Clinical Trial ◽

Ischemic Events ◽

Thrombin Receptor Antagonist ◽

Selection Of

Download Full-text

thrombin receptor antagonist
Recently Published Documents

TOTAL DOCUMENTS

H-INDEX

Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial

Effect of age on efficacy and safety of vorapaxar in patients with non–ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)‐TIMI 50

TRADEOFF BETWEEN MYOCARDIAL INFARCTION VERSUS BLEEDING TYPES ON MORTALITY AFTER ACUTE CORONARY SYNDROME: LESSONS FROM THE THROMBIN RECEPTOR ANTAGONIST FOR CLINICAL EVENT REDUCTION IN ACUTE CORONARY SYNDROME (TRACER) RANDOMIZED TRIAL

In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist

Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist

Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non–ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)

Efficacy and Safety of Thrombin-Receptor Antagonist (Atopaxar and Vorapaxar) in Patients with Acute Coronary Syndrome or Coronary Artery Disease—A Meta-Analysis of Randomized Controlled Trials

Selection of a Suitable Patient Population for New Antiplatelet Therapy From the Large Clinical Trial Database of the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events–Thrombolysis in Myocardial Infarction 50 (TRA-2P–TIMI50) Trial

Export Citation Format

thrombin receptor antagonistRecently Published Documents

TOTAL DOCUMENTS

H-INDEX

Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial

Effect of age on efficacy and safety of vorapaxar in patients with non–ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)‐TIMI 50

TRADEOFF BETWEEN MYOCARDIAL INFARCTION VERSUS BLEEDING TYPES ON MORTALITY AFTER ACUTE CORONARY SYNDROME: LESSONS FROM THE THROMBIN RECEPTOR ANTAGONIST FOR CLINICAL EVENT REDUCTION IN ACUTE CORONARY SYNDROME (TRACER) RANDOMIZED TRIAL

In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist

Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist

Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non–ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)

Efficacy and Safety of Thrombin-Receptor Antagonist (Atopaxar and Vorapaxar) in Patients with Acute Coronary Syndrome or Coronary Artery Disease—A Meta-Analysis of Randomized Controlled Trials

Selection of a Suitable Patient Population for New Antiplatelet Therapy From the Large Clinical Trial Database of the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events–Thrombolysis in Myocardial Infarction 50 (TRA-2P–TIMI50) Trial

thrombin receptor antagonist
Recently Published Documents